Life Science Practice
Edgewater’s Life Science Practice is focused on companies that create value by providing critical products or services towards the development or manufacture of pharmaceuticals, biopharmaceuticals, diagnostics, and medical devices. The dynamic and rapidly growing target verticals are focused on companies providing pharmaceutical fine chemicals, pharmaceutical services (CRO, CDMO, CMO, and niche specialist players), and companies offering differentiated reagents, materials, and technologies to the pharma industry.
Overview
View our Pharma Chemicals teaser
Media
CPHI Annual Report 2022 – CRO/CDMO’s in Uncertain Economic Times
CPHI Annual Report 2023 – A Year of Realignment for the CRO/CDMO Sector
CPHI Annual Report 2024 – An Update on the Health of the CRO/CDMO Sector
Target Industries, End Markets, or Applications
Practice Leader: Brian Scanlan
bscanlan@edgewatercapital.com
Office: (216) 292-3838
Brian leads Edgewater’s Life Science practice and is engaged with several portfolio companies in advisory roles spanning commercial, operational, and Board advisory. Brian has spent nearly three decades in the pharmaceutical services sector, developing and growing companies offering highly differentiated technologies and services. He is also the Founder and Managing Partner of Freedom Bioscience Partners, a consultancy firm focused on M&A and strategic business advisory to the pharmaceutical and fine chemical industries. Prior to launching Freedom, Brian served as CEO at Cambridge Major Laboratories, a global pharma contract development and manufacturing organization (CDMO) focused on active pharmaceutical ingredients, solid state chemistry, and analytical services.
Brian holds a BS in Chemistry from Northern Illinois University and an MBA from the Illinois Institute of Technology.
Executive Partner: Kirt Poss
Kirt Poss is an Executive Partner with Edgewater Capital Partners in the Life Science practice. Mr. Poss brings more than 25 years of CEO healthcare leadership and business growth experience to Edgewater. Most recently, he served as CEO-US of ProtaGene, a leading provider of advanced analytics in biopharmaceutical platform development, which was formed in a PE-backed M&A in 2021. Previously, he founded and served as CEO of BioAnalytix, where he led the company from early commercial growth through M&A with Protagen Protein Services in 2019. Before founding BioAnalytix, Mr. Poss co-founded and served as CEO of the biomarker imaging company VisEn Medical from its early product development through worldwide commercialization and M&A with PerkinElmer in 2010. Before that, Mr. Poss worked in healthcare business strategy consulting in Cambridge, MA, where he focused in the pharmaceutical and medical device sectors. Earlier in his career, Mr. Poss worked in scientific research at the Center for Molecular Imaging Research at the MGH and Harvard Medical School. Before transitioning into science, Mr. Poss earned a BA in Political Science and English from the University of Connecticut.
Relevant Portfolio Companies
